Prescription patterns of comorbidity-related medication at baseline and after 24 weeks in the study population
| Pharmacological class, n (%) | HT (N=1642) | HT (N=1635) | Obesity* (N=2298) | Obesity* (N=2285) | T2DM (N=477) | T2DM (N=475) | High cholesterol (N=2122) | High cholesterol (N=2119) |
| Baseline | At 24 weeks | Baseline | At 24 weeks | Baseline | At 24 weeks | Baseline | At 24 weeks | |
| Beta-blockers | 234 (14.3) | 228 (13.9) | 186 (8.1) | 179 (7.8) | 51 (10.7) | 50 (10.5) | 195 (9.2) | 192 (9.1) |
| Diuretics | 181 (11.0) | 185 (11.3) | 152 (6.6) | 160 (7.0) | 26 (5.5) | 31 (6.5) | 141 (6.6) | 146 (6.9) |
| ACE inhibitors | 588 (35.8) | 585 (35.8) | 467 (20.3) | 465 (20.4) | 105 (22.0) | 105 (22.1) | 445 (21.0) | 452 (21.3) |
| Sartans | 368 (22.4) | 364 (22.3) | 307 (13.4) | 304 (13.3) | 81 (17.0) | 77 (16.2) | 291 (13.7) | 294 (13.9) |
| Other hypotensive medications | 221 (13.5) | 217 (13.3) | 188 (8.2) | 183 (8.0) | 56 (11.7) | 56 (11.8) | 182 (8.6) | 178 (8.4) |
| Statins | 466 (28.4) | 468 (28.6) | 601 (26.2) | 583 (25.5) | 111 (23.3) | 115 (24.2) | 698 (32.9) | 677 (32.0) |
| Biguanides | 162 (9.9) | 173 (10.6) | 239 (10.4) | 246 (10.8) | 241 (50.5) | 247 (52.0) | 208 (9.8) | 218 (10.3) |
| Other hypoglycaemic medications†| 72 (4.4) | 68 (4.2) | 93 (4.0) | 85 (3.7) | 107 (22.4) | 104 (21.9) | 83 (3.9) | 77 (3.6) |
| Others | 268 (16.3) | 172 (10.5) | 332 (14.5) | 208 (9.1) | 73 (15.3) | 44 (9.3) | 334 (15.7) | 211 (10.0) |
| No treatment | 343 (20.9) | 371 (22.7) | 898 (39.1) | 954 (41.8) | 71 (14.9) | 77 (16.2) | 756 (35.6) | 810 (38.2) |
Percentages are calculated as n/N. Some patients (%) with multiple comorbidities were included in several columns.
*Or overweight.
†Including sulfonylureas (ie, gliclazide, gliquidone, glimepiride, and glibenclamide), insulin, inhibitors of dipeptidyl peptidase-4 (ie, vildagliptin, sitagliptin, saxagliptin, and linagliptin), repaglinide, and acarbose.
HT, hypertension; T2DM, type 2 diabetes mellitus.